📈 Why Menopause Tech Is Booming — and Why It Deserves Scrutiny

Perimenopause typically begins in a woman’s mid-40s, though it can start in her 30s, bringing hot flashes, night sweats, sleep disruption, mood changes, and cognitive symptoms often described as “brain fog.” For decades, the primary tools for managing it were a conversation with a doctor and, for many women, hormone therapy.

That’s the context worth holding onto: this technology wave is arriving in a space where the established medical treatment is well studied, but the tracking and comfort tools built around it are brand new. The 2022 Hormone Therapy Position Statement from the North American Menopause Society — the organization renamed itself The Menopause Society in 2023, though the statement was published under its earlier name — remains the field’s leading clinical guidance document. It states that hormone therapy is the most effective treatment available for vasomotor symptoms like hot flashes, and that it has also been shown to help prevent bone loss and fracture. Risk and benefit should be individualized by age and time since menopause onset, with the most favorable profile generally found in women under 60 who are within ten years of menopause onset.

That’s the category’s real Tier 1 benchmark. Almost none of the consumer tech below claims to replace it — most of these products describe themselves as complementary tools for tracking, comfort, or non-hormonal symptom relief. Readers experiencing bothersome symptoms should treat a conversation with a clinician as the starting point, not an accessory to the tech.

🔬 A Four-Tier Framework for Evaluating Menopause Tech

Before looking at specific products, it helps to have a consistent way to sort their claims.

• Tier 1: Established evidence. Large-scale, peer-reviewed, ideally replicated research — the kind behind hormone therapy itself. No consumer menopause wearable or app has independently reached this bar for its specific symptom-relief claims.
• Tier 2: Early or preliminary research. Genuine peer-reviewed publications, with real caveats: small samples, pilot-study design, or research conducted in partnership with the company selling the product. Real signal, not nothing — but not an independently replicated, large-scale trial either.
• Tier 3: Manufacturer claims only. Statements in company marketing, press releases, or product pages with no identifiable independent or peer-reviewed source behind them. Not necessarily false — just unverifiable against a published study as of this writing.
• Tier 4: Tracking tools, not treatment claims. Apps and platforms designed to log symptoms and patterns for personal reference or a doctor’s appointment. Because they aren’t claiming to treat or relieve anything, they don’t carry the same evidentiary burden — though data accuracy and privacy still matter.

⌚ Purpose-Built Perimenopause Wearables

Embr Wave

Embr Wave is a wrist-worn thermal device that delivers warming or cooling sensations. It’s one of the few products in this space with actual peer-reviewed research behind it, placing its core claim in Tier 2 — with an important caveat below.

The verified study. Composto, Leichman, Luedtke, and Mindell published “Thermal Comfort Intervention for Hot-flash Related Insomnia Symptoms in Perimenopausal and Postmenopausal-aged Women: An Exploratory Study” in Behavioral Sleep Medicine (DOI: 10.1080/15402002.2019.1699100). We located and reviewed the study directly rather than relying on a secondhand summary. Forty women were enrolled and 39 completed it, ages 45 to 58, average age 52, following a baseline period and then a period using the device. It was a single-arm, pre/post exploratory pilot — no control group, no randomization, a meaningfully lower bar than a randomized controlled trial. Two independent sources describing the results agree that roughly two-thirds of participants (66%) reported improved thermal comfort and improved ability to return to sleep after waking. That figure holds up across independent accounts of the study.

Embr also cites a UMass Amherst collaboration on an AI-driven algorithm that predicts hot flashes before they’re consciously perceived, described in a press release as “featured in the journal Psychophysiology,” with roughly 70% of hot flashes anticipated in advance. We reviewed this through the press release rather than the underlying journal article, so we’re citing it with that caveat: plausible, and naming a real, indexed journal, but not independently pulled from the primary paper.

Beyond menopause, Embr Wave has been studied in adjacent populations. A pilot trial registered on ClinicalTrials.gov evaluated the device in women with a history of breast cancer experiencing hot flashes — around 30 participants at the Ohio State University Comprehensive Cancer Center, explicitly a feasibility study rather than a definitive efficacy trial. Separately, Embr Labs partnered with the Dana-Farber Cancer Institute on a study of the device in men undergoing hormone therapy for prostate cancer, published in Prostate Cancer and Prostatic Diseases — useful supporting evidence for the underlying thermal mechanism, though not a menopause-specific result, and one we also reviewed via press release rather than the primary paper.

Peri (IdentifyHer)

Peri is a wearable biosensor worn on the upper abdomen that tracks hot flashes, night sweats, sleep, and activity through continuous biometric monitoring. It was named a CES Honoree and is now available for direct order. The company describes its dataset as the first large-scale collection of continuous perimenopause biometric data, intended to improve long-term clinical understanding of the transition.

The CES recognition is real. The “first large-scale dataset” framing, however, comes from the company’s own press materials, and we found no independent, peer-reviewed publication of results from that dataset at the time of writing. That puts Peri in Tier 3: a genuinely interesting hardware approach with industry recognition, not yet backed by published research. Watch for peer-reviewed publications as the product matures, rather than treating today’s marketing claims as settled science.

📱 Mainstream Wearables Adding Menopause Features

Oura

Oura, already established as a sleep and recovery tracker, has expanded into this space with a Perimenopause Check-In feature and a broader “Oura Advisor” AI tool built to answer questions about biometric data in the context of menstrual cycles, fertility, and menopause. The company has also partnered with Maven Clinic to help integrate signals like temperature and heart rate into care conversations.

The Maven Clinic partnership is a legitimate step toward clinical relevance. But we found no independently published, peer-reviewed validation of Oura’s perimenopause-specific accuracy, as distinct from its more broadly studied sleep- and temperature-tracking capabilities. That lands Oura’s menopause-specific features in Tier 3 for now — a well-established wearable extending into a new use case faster than independent research has caught up.

Eight Sleep

Eight Sleep, known for its smart mattress technology, introduced a “Hot Flash Mode” that responds to temperature fluctuations in real time, described as informed by data from over 1,200 menopausal women. We found no published study or white paper detailing that dataset or its methodology — the figure traces back to company statements, not an independently verifiable source. Until that changes, treat the “1,200 women” figure as a marketing data point rather than a peer-reviewed result, and file this one under Tier 3.

Evie Ring

Evie Ring markets itself with “medical-grade” language and positions itself as HSA/FSA-eligible, which can read as formal medical clearance. It isn’t: HSA/FSA eligibility is a tax and reimbursement classification, not a marker of FDA clearance or clinical validation. It’s worth confirming what regulatory status, if any, underlies “medical-grade” language before assuming it means clinically validated for menopause symptom tracking. We’d place this claim in Tier 3 pending clearer documentation.

⚖️ The Regulatory Reality Behind “Medical-Grade” Claims

Phrases like “medical-grade,” “clinically proven,” and “clinically validated” show up constantly across this category, and it’s worth understanding why. In the United States, most consumer wearables — including everything discussed here — are marketed as general wellness products rather than regulated medical devices, a meaningfully lower bar than the review process for a device cleared to diagnose or treat a condition. A product can be well-engineered and genuinely useful for tracking while still sitting outside formal medical device review, and the marketing rarely makes that distinction clear.

This isn’t unique to menopause tech; digital health regulators are still working through how to evaluate consumer-facing health technology broadly, including oversight frameworks for AI-driven health tools.

The practical takeaway: if a product leans hard on “medical-grade” or “clinical,” ask what specific regulatory clearance, if any, backs that claim, rather than taking the phrase at face value.

📝 Tracking Apps vs. Treatment Devices: A Different Risk Category

Do you need clinical-trial evidence for a symptom-tracking app? Generally, no — and that’s an important distinction. Clue, Flo, Balance, and Health & Her are largely Tier 4 products: designed to log symptoms, identify patterns, and generate reports for a healthcare provider, not to treat or relieve symptoms directly.

Balance, for instance, was created by Dr. Louise Newson, a UK-based menopause specialist, and focuses on structured symptom tracking alongside educational content. Because these tools aren’t claiming a physiological treatment effect, the relevant questions shift:

• How well does the app handle the irregular, unpredictable cycles typical of perimenopause, where cycle length can swing dramatically rather than follow a pattern?
• Does it integrate with a wearable you already own?
• Given how much personal health data you’re sharing, what are its privacy practices — is data sold, and can you export it for a doctor’s visit?

🩺 Telehealth and Clinical-Support Tools

Not everything here is a wearable or an app. Midi Health is a telehealth platform built around menopause care, connecting patients with clinicians and working with insurance coverage for many users — a fundamentally different model, since a licensed clinician is involved in care decisions rather than an algorithm alone.

At the other end of the spectrum, MENO.pause is a digital decision-support tool developed by clinicians at University College London Hospitals and University College London, designed to help doctors translate national guidelines into consultation support. It isn’t a consumer product — it exists to support the clinicians treating patients, which makes it a useful marker of where more rigorous, guideline-based tools in this space are headed, even if it’s not something you’d download yourself.

📊 Quick Comparison

⚠️ Common Mistakes When Reading Menopause Tech Marketing

• Treating a Tier 3 marketing claim as Tier 2 evidence. Embr’s own J&J-trial percentages are a good example — real peer-reviewed research exists for the product, but those specific figures aren’t part of it.
• Assuming HSA/FSA eligibility means FDA clearance. It’s a tax and reimbursement classification, not a marker of clinical validation, whatever “medical-grade” language sits next to it.
• Assuming “clinically studied” language points to a findable published study. If you can’t locate the paper, treat the claim as Tier 3 until you can.
• Holding a Tier 4 tracking app to the same evidence bar as a treatment device. The real question for a tracking app is privacy and data handling, not clinical proof.
• Letting a wearable or app substitute for a conversation with a clinician about bothersome symptoms, rather than supplementing it.

✅ Questions to Ask Before You Buy Any Menopause Device

Given how young and fast-moving this category is, a checklist does more work than another product review:

• Is it claiming to treat or relieve a symptom, or just track it? These require very different levels of evidence.
• Is there a published, peer-reviewed study behind the specific claim — not just “clinically studied” language, but a findable study?
• Who funded or conducted the research? Company-affiliated studies aren’t automatically wrong, but they warrant a more skeptical read than independently funded ones.
• What does “medical-grade” or “clinically proven” actually mean for this product? Neither phrase has a fixed regulatory definition, and both get used loosely in wellness marketing.
• If it’s a tracking tool, how does it handle irregular cycles, and what’s its data privacy policy?

Asking these before purchasing saves money and sets realistic expectations for what a device can and can’t do.

🎯 Who This Technology Is Actually Right For

If you’re comfortable with early-stage, promising-but-unproven technology, and understand you’re an early adopter rather than using a clinically validated treatment, several of these products — Embr Wave in particular, given its comparatively stronger research base — may be worth exploring as a non-hormonal comfort measure.

If bothersome symptoms are affecting your daily life, the evidence-backed starting point is still a conversation with a healthcare provider about options like hormone therapy, which the Menopause Society’s position statement identifies as the most effective treatment for vasomotor symptoms in most healthy women under 60 within ten years of menopause onset. Wearables and apps can usefully supplement that care — tracking patterns, generating data for a doctor, managing day-to-day comfort — but none of them should substitute for it based on the evidence available today.

If you simply want to understand your own patterns — cycle changes, sleep disruption, mood shifts — a Tier 4 tracking app paired with a wearable you already own is a low-risk, genuinely useful starting point, with privacy practices the main thing to vet.

❓ Frequently Asked Questions

Is any menopause wearable FDA-cleared to treat symptoms?

No product covered here claims FDA clearance for treating menopause symptoms. Most consumer menopause wearables and apps are marketed as general wellness products, not regulated medical devices — hormone therapy remains the field’s established Tier 1 treatment.

What’s the difference between Tier 2 and Tier 3 evidence in this category?

Tier 2 means a genuine peer-reviewed study exists, even if small or company-affiliated — Embr Wave’s core sleep-related claim is the clearest example. Tier 3 means the claim appears only in company marketing or press releases with no independently verifiable published study behind it — true of most other products discussed here.

Does HSA/FSA eligibility mean a product is medically validated?

No. HSA/FSA eligibility is a tax and reimbursement classification, not a marker of FDA clearance or clinical validation, even when a product also uses “medical-grade” language.

Should tracking apps be held to the same evidence standard as treatment devices?

No. Apps like Clue, Flo, Balance, and Health & Her generally aren’t claiming to treat or relieve symptoms, so the more important questions for them are how they handle irregular perimenopausal cycles and how they protect user data, not clinical proof.

What’s still the most evidence-backed option for bothersome menopause symptoms?

Hormone therapy, per the Menopause Society’s 2022 position statement, remains the most effective treatment for vasomotor symptoms like hot flashes in most healthy women under 60 within ten years of menopause onset. It should be discussed with a healthcare provider rather than replaced by consumer tech.

📚 Sources & References

• The North American Menopause Society, “The 2022 Hormone Therapy Position Statement of The North American Menopause Society,” Menopause, Vol. 29, No. 7, 2022 (organization renamed The Menopause Society in 2023)
• Composto, J., Leichman, E. S., Luedtke, K., & Mindell, J. A., “Thermal Comfort Intervention for Hot-flash Related Insomnia Symptoms in Perimenopausal and Postmenopausal-aged Women: An Exploratory Study,” Behavioral Sleep Medicine, DOI: 10.1080/15402002.2019.1699100
• EurekAlert!, “Hot flashes can be reliably predicted by an ai-driven algorithm developed by UMass Amherst and Embr Labs” (press release describing the Psychophysiology publication)
• ClinicalTrials.gov, NCT05086705 — “EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer,” Ohio State University Comprehensive Cancer Center
• PR Newswire, “Embr Labs Announces Publication of Groundbreaking Study on Hot Flashes in Prostate Cancer Patients in Prestigious Nature Journal” (press release describing the Prostate Cancer and Prostatic Diseases publication)
• Embr Labs, support page describing the Johnson & Johnson Innovation trial (company-sourced; figures cited there could not be independently corroborated — see caveat above)
• FemTech World, “Best menopause apps and products for 2026”
• Contemporary OB/GYN, “Wearable device designed for perimenopause launches” (Peri/IdentifyHer)
• TechBullion (via MEXC), “Top FemTech Trends to Watch in 2026: AI, Wearables, and Personalized Health”

Verification notes: The Composto et al. study was independently located and reviewed directly (not via a secondhand summary) — it is a small (n=39), single-arm, uncontrolled exploratory pilot, and should be read as such. The specific J&J-trial percentage figures (168% improvement, 28% reduction in sleep onset latency) appear only in Embr’s own company materials and could not be matched to the published paper’s methodology; they are labeled as an unverified manufacturer claim above. Eight Sleep’s “1,200 women” Hot Flash Mode claim and Evie Ring’s “medical-grade” language likewise could not be independently verified against a published study and are labeled accordingly.

💡 Final Thoughts

Menopause technology is advancing quickly, and some of it is genuinely promising. But as of today, most of the category sits somewhere between “early research” and “manufacturer claim” — not “proven.” That’s not a knock on the field; it’s an accurate description of where the evidence stands, and it’s the kind of baseline that’s often missing from product roundups built around affiliate links.

The most useful thing to take from this article isn’t a specific product recommendation. It’s the four-tier framework itself — treatment claim or tracking tool, independent research or company claim, large-scale or pilot-scale. Apply it to whatever launches next, and you’ll be equipped to tell a genuine advance from a well-marketed guess.

For more on how wearable accuracy and marketing claims play out in other health categories, see our testosterone and hormone optimization guide and our cuffless blood pressure wearables coverage.